The nation of Zimbabwe has declined a significant American healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's request for sensitive information.
The decision came to light following a government memo from December was leaked, indicating that President Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesperson has since clarified that the US was requesting health data for research and commercial purposes but was unwilling to guarantee the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate process of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged continued negotiations to reach a agreement acceptable to both sides so the country's critical HIV treatment initiative can continue.
Wider Background
This rejection follows a similar case in neighbouring Kenya, where a court blocked a related deal with the US following concerns were raised about the security of Kenyans' health data.
After returning to office last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump claimed its spending was "wasteful" and his government was seeking government-to-government deals to boost openness and responsibility.
Based on statements, 16 nations in Africa have so far signed similar health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation might have yielded immense advantages for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment through American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data for a long time, with no equivalent promise of benefiting from any medical innovations – such as new medicines or tests – that might result from that shared data," Mangwana explained.
"In essence, our nation would provide the raw materials for medical research with no certainty that the final treatments would be available to our population should a new pandemic arise."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were disrupting structures previously established via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential pandemics.
"This framework is designed to guarantee that when a nation contributes its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome continued discussions with our American counterparts on how subsequent collaboration could be designed in a way that honours the sovereignty and dignity of each country."
Medical Community Response
Medical experts said it acknowledged the official position, but suggested that talks should continue given that much of the nation's Aids initiatives depended on external financing.
"In cases where technical issues exist, such as those involving data governance or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," it commented.
The halted deal highlights the continuing challenges between receiving crucial international aid and protecting a country's data in an increasingly data-driven world.